Seoul Pharma

서울제약 · 018680

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$18.5M (₩25.5B)

Overview

Seoul Pharma makes prescription medicines, including digestive and acid-relief tablets, supplied to patients through the South Korean healthcare system.

It is listed on KOSDAQ, Korea's tech and small-cap exchange. The company is actively developing improved-formulation drugs, with a particular focus on a proprietary oral dissolving film technology it calls SmartFilm®, and has completed construction of a new facility built to internationally recognised current Good Manufacturing Practice standards to support entry into advanced markets.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$37.8M

▼ −2.7% YoY

Operating profit · FY2025

−US$927.1K

Turned to loss

Net income · FY2025

US$546.1K

▼ −55.6% YoY

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$38M(₩52.5B)	US$38.8M(₩53.6B)	US$37.8M(₩52.1B)
Operating profit	US$878.8K(₩1.2B)	US$1.1M(₩1.5B)	−US$927.1K(−₩1.3B)
Net income	US$2.5M(₩3.5B)	US$1.2M(₩1.7B)	US$546.1K(₩753.6M)

Revenue

FY2023US$38M
FY2024US$38.8M
FY2025US$37.8M

Operating profit

FY2023US$878.8K
FY2024US$1.1M
FY2025−US$927.1K

Net income

FY2023US$2.5M
FY2024US$1.2M
FY2025US$546.1K

Key ratios (FY2025)

ROE

1.8%

Debt/Eq

74.8%

Op. margin

-2.5%

Net margin

1.4%

Rev. YoY

▼ −2.7%

Why it matters

Seoul Pharma has completed a new cGMP-standard manufacturing facility in Osong, South Korea, aimed at enabling entry into the US and other advanced pharmaceutical markets.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?